PD-1 Blockade in Tumors with Mismatch-Repair Deficiency - Wikidata - awgldk - TriplyDB

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

http://www.wikidata.org/entity/Q28262647

about

PD-L1 expression in human cancers and its association with clinical outcomes The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients DNA damage, tumor mutational load and their impact on immune responses against cancer Towards tumor immunodiagnostics Neoantigen-based cancer immunotherapy Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Genomic diversity of colorectal cancer: Changing landscape and emerging targets Cytotoxic and targeted therapy for hereditary cancers Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer New targeted treatments for non-small-cell lung cancer - role of nivolumab PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Molecular pathological classification of colorectal cancer Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Checkpoint Inhibitors and Their Application in Breast Cancer Current and emerging therapies in unresectable and recurrent gastric cancer Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer Epigenetic therapy in gastrointestinal cancer: the right combination Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma Prime time for immune-checkpoint targeted therapy at ASCO 2015 The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis Surgical and molecular pathology of pancreatic neoplasms Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Dendritic cell-based cancer immunotherapy for colorectal cancer Heritable Cancer Syndromes Related to the Hypoxia Pathway Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer PD-1/PD-L1 blockades in non-small-cell lung cancer therapy Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Novel targets in the treatment of advanced gastric cancer: a perspective review Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer Signaling in T cells - is anything the m(a)TOR with the picture(s)?PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity Novel therapeutic agents in the treatment of metastatic colorectal cancer

P2860

Q26738361-3EE60B1E-1D2A-4C76-9461-4F71AB8A1121 Q26738665-916F60FD-D805-4A01-92C8-6B53615DBEFC Q26738685-916638CA-55ED-4D18-A58C-7A9BCCAABF60 Q26738691-CC69F4B9-5806-4F69-BF94-0520904B99F9 Q26738693-69692BD5-6224-4AE7-9C89-8CD79EE92856 Q26738801-3042FF9E-3475-4E47-BE94-44D7EEB924D7 Q26739052-3AC3D0D3-E160-469C-A7E7-6AA4399DCEF7 Q26739366-03D42811-D46C-4EB9-9A59-61A5507F1665 Q26740288-EB5DB4A2-2895-437D-8F4D-877EE4AF0884 Q26740988-859AAC69-BCCA-469A-ADB9-E057AD8D103A Q26741101-4CBFB6D7-F994-4537-83BE-8A8060D29501 Q26744251-0608208D-E0C8-4D45-8C12-3A5726166CE8 Q26744758-7A007A93-8C07-4788-BA47-FE32F5578E49 Q26745442-D5697760-80EC-4423-8781-51C865797F28 Q26745453-62410DF2-687A-425A-83DD-1263AB572E25 Q26745516-2CD2CF77-6495-4583-87EE-5CB0446EEAB2 Q26745580-258265FE-3A84-4E61-8BA0-AA7806533414 Q26745590-213F45DE-F07F-4ABA-823B-3F9990F55FA2 Q26745709-EEE92403-DE35-42A7-B01A-A44BC5F8D889 Q26747329-912BC87C-4611-41EA-9727-72899EFC6E12 Q26747339-0CF95442-613C-443D-A6E0-FF5C7AAC21D7 Q26747711-B1705D2C-BD0A-4A18-A8B4-D4E213D8A27F Q26748194-6DE27F47-4F20-44F2-90D6-24EDC0133272 Q26748615-92CA096A-B5C8-46F3-9759-EB59028BF96D Q26750190-142514AB-195B-402A-98AE-EA6CCFE81F41 Q26751224-6D0C2D08-DE19-48A7-B4D8-7A76D05040B0 Q26751339-1BEE0C68-960B-4B4F-960B-AAA81A4E28AE Q26751590-C60B8CAC-02CE-4E78-B1C9-CCF554B197F6 Q26752491-0495532A-FD10-4123-8421-BB24CA04DD18 Q26765024-90D457BD-9496-4CCA-9F76-C1F172EB5316 Q26765060-73B497DA-3F10-4693-89B9-C4B0ABEFAC05 Q26765123-3A66654A-D065-4090-891E-F568B1AC237D Q26765208-6184F25A-8CDB-4DB1-AB50-4E0AD730DDE0 Q26765459-EE9A0891-AF06-4619-9A44-1B8F77C1E642 Q26766285-E9E6EF15-759E-4AC8-AD82-B174467B49B3 Q26767443-9D067196-BB59-4A7D-B885-8748AB8B473D Q26768641-E738374D-510B-48F0-9AE9-6AF70FBF08D5 Q26768659-EB025892-428A-4A86-B0D0-F3B873465440 Q26769744-6E03F233-4C89-4ADA-8566-2BB6D8106E0D Q26769932-A5803522-F76C-429D-87F8-9901E06A1C84

P2860

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

http://www.wikidata.org/entity/Q28262647

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@ast

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@en

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@nl

type

label

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@ast

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@en

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@nl

prefLabel

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@ast

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@en

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@nl

P1433

Q28262647-0F38DAE1-EE4C-41EE-B15F-166BBF60167F

P1476

Q28262647-AA9EF1C5-1E61-40FE-A949-5B9C327BD300

P2093

Q28262647-0B23D707-FDE1-4AC5-B4FC-3C2ED730BA6B

Q28262647-0E2ECA7A-47E7-4188-A88C-01826EFE6BA3

Q28262647-1D1B3162-6E87-4DC7-9F1F-11E1238BC712

Q28262647-25B1EF85-645E-4EB9-AD87-43F5250F0808

Q28262647-33E38CF1-6F14-4D10-B4B2-E65CA7BC6644

Q28262647-3A63AF4D-6F14-42DB-8904-D42DEE202AF8

Q28262647-3DA3268E-F383-4F04-B577-0D61E7854679

Q28262647-4F3D73CD-63DA-43E0-B16C-D238E02078F4

Q28262647-4FF0BC3A-21AB-4AA7-9CC2-FE4A9DB2BE15

Q28262647-5E6AAAE6-4F6C-4256-86EB-3E6531319FE0

P2860

Q28262647-0143C8DF-9E3A-42CE-976C-F3606C3706F9

Q28262647-109AB67C-1315-4DA6-B3CA-1D6D926BF03A

Q28262647-24F61723-8355-4E91-9C60-9E186EEDDF55

Q28262647-2670A441-48A5-4F8E-B5AB-60DE4F21804A

Q28262647-2C86A1A6-32CB-4043-A336-D48756D6AF48

Q28262647-2F10643E-45BE-41C4-8D6F-CDFA0B3AC739

Q28262647-30C4B940-CE2F-4E1F-A70F-1C24ED7FFD0D

Q28262647-32D4E804-C3BB-4CA7-A6C3-53EB0F7667FC

Q28262647-3F174733-599C-4CD0-A5A2-7D8F13CCEAB7

Q28262647-4672A0EB-F624-4F91-892E-275ABC9AD309

P304

Q28262647-D870E9F3-E3B3-4519-9660-226089E0614C

P31

Q28262647-CC777394-BD22-442C-B8A4-AA65496FBD1B

P3181

Q28262647-CC6319C5-4F1D-44C9-8469-573DEBF3A46A

P356

Q28262647-ACE72275-BC66-459C-9427-F17B225033B7

P407

Q28262647-7C29A98F-F6E1-4881-A961-EA4CB33D45EE

P433

Q28262647-03EC804D-672B-4997-A138-B833582B0242

P478

Q28262647-0463BD62-B08F-466C-A0D1-D52BBC25A914

P50

Q28262647-01FBCCBB-9388-43ED-BFF3-1F5E021F5EF1

Q28262647-38896EF7-A084-4DD2-93C2-96FF88C0EB20

Q28262647-46443E4D-C09A-445D-985C-BF1D2D4EC964

Q28262647-6651EA04-6A67-4CEE-877D-FA3D6E7A230D

Q28262647-6A475E06-65DD-4222-87C5-B6B88144ACD0

P5008

Q28262647-1E79C58F-CAB9-4E29-9959-F5EF9D3CF2C8

P577

Q28262647-E4E82C51-EAC4-4CE4-A8B8-3404C81DC2F1

P698

Q28262647-21223B94-C75C-4F8A-92AC-790992E1A988

P921

Q28262647-06da9fc4-4b29-2a30-3820-25b6fb310852

Q28262647-07910291-4fde-9c91-e5aa-510ffec68da5

Q28262647-3893b4ec-46d5-1e74-84eb-12f390c8754f

Q28262647-459c5661-4592-fada-004c-41e06d237349

Q28262647-779ae943-4e3e-e07c-beac-b5839c91d432

Q28262647-b58bbd4c-4979-ea71-386b-8697725877f5

P932

Q28262647-5894B5A0-5D0D-4672-B55D-7BC2C3C96E86

P3181

P356

P1433

The New England Journal of Medicine

P1476

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

@en

P2093

Aleksandra D Eyring

http://www.w3.org/2001/XMLSchema#string

Andrew D Skora

http://www.w3.org/2001/XMLSchema#string

Atif Zaheer

http://www.w3.org/2001/XMLSchema#string

Barbara Biedrzycki

http://www.w3.org/2001/XMLSchema#string

Brandon S Luber

http://www.w3.org/2001/XMLSchema#string

Dan Laheru

http://www.w3.org/2001/XMLSchema#string

Drew M Pardoll

http://www.w3.org/2001/XMLSchema#string

Dung T Le

http://www.w3.org/2001/XMLSchema#string

Feriyl Bhaijee

http://www.w3.org/2001/XMLSchema#string

George A Fisher

http://www.w3.org/2001/XMLSchema#string

P2860

Melanoma genome sequencing reveals frequent PREX2 mutations

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

Microsatellite instability in colorectal cancer

Comprehensive molecular characterization of human colon and rectal cancer

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Liquid biopsies: genotyping circulating tumor DNA

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

P304

2509-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

132331

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1500596

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Ralph H. Hruban

Kenneth W Kinzler

Bjarne Bartlett

Albert de la Chapelle

Bert Vogelstein

P5008

P577

2015-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26028255

http://www.w3.org/2001/XMLSchema#string

P921

Programmed cell death 1

DNA mismatch repair

phase II clinical trial

humanized antibody

P932

4481136

http://www.w3.org/2001/XMLSchema#string